Free Trial

3 Small-Cap Stocks For Your Fall Shopping List

3 Small-Cap Stocks For Your Fall Shopping List
3 Small-Cap Stocks For Your Fall Shopping List

Small-cap stocks are loosely defined as companies with a market capitalization of less than $2 billion dollars. When they are compared to large- and mid-cap companies, small-cap stocks are typically seen as having better growth potential.

By nature, small-cap stocks are subject to volatile price swings that make them appropriate only for risk-tolerant investors. One such risk is that many small-cap companies are newer entries into their field. And depending on where they are in their business cycle, they may require access to a lot of capital which can be hard to acquire.

However, if you have a tolerance for risk, these stocks have the potential for gains that exceed that of the broader market. Like any asset class, doing your due diligence is a necessity. This is another good reason to become a MarketBeat All Access member. You’ll get access to features such as a list of the Top-Rated Small-Cap Stocks. With that in mind, here are three stocks for you to add to your watch list.

Purple Innovation (NASDAQ: PRPL) – For obvious reasons, PRPL stock did very well during the pandemic. Many people sought to improve the quality of their homes and health. And, for many, this meant buying Purple Innovation’s products to make their home more comfortable. Revenue was up 51% in 2020 and earnings per share were up 80% as compared to 2019.

But you shouldn’t dismiss Purple Innovation as being just a pandemic play. For the first half of 2021, revenue is on pace to be higher than 2020 although earnings look to be lower. That could be weighing on the stock which is trading near its 52-week lows. Plus, one analyst just downgraded the stock. However, the consensus price target of analysts has PRPL stock trading at around $35 per share.

ThredUp (NASDAQ: TDUP) – The next small-cap stock that should be on your watch list is ThredUp. This is an online consignment store that has been in business since 2009. TDUP has only been trading publicly since March 2021. In that time, the stock has shown plenty of volatility and is undoubtedly frustrating investors because it’s trading right around its initial public offering (IPO) price.

But with small-cap stocks, it’s less about where the stock has been then about where it’s going. In this case, analysts are giving TDUP stock a $26 price target. If I was to be concerned about anything, it’s that the stock has a high short percentage of float. That means that it will be popular with short-term traders who are looking to capitalize on a short-term trade. But with inflation and supply chain challenges likely to be around for several quarters, shopping secondhand has never looked thriftier.

Taysha Gene Therapies (NASDAQ: TSHA) – The last of the small-cap stocks on this list is the one with the most risk, but also the greatest potential upside. The field of gene therapy will be one of the hottest fields of biotechnology in the next decade. Taysha Gene Therapies is focused on eradicating monogenic diseases of the central nervous system. Monogenic disorders are caused by variation in a single gene.

Many biotech companies are pre-revenue companies which means the pipeline is critical. And Taysha currently has 26 Adeno-Associated Virus (AAV)-based gene therapies under development. Several of these candidates are approaching critical stages that could lead to them making it through the clinical trial stage.

At this time, analysts have a price target of over $44 for TSHA stock. Short interest remains a little high, but that’s not unusual for small-cap stocks.

Should You Invest $1,000 in Taysha Gene Therapies Right Now?

Before you consider Taysha Gene Therapies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.

While Taysha Gene Therapies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Chris Markoch
About The Editor

Chris Markoch

Editor & Contributing Author

Contributing Author

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Taysha Gene Therapies (TSHA)
2.6537 of 5 stars
$4.94flatN/A-14.53Moderate Buy$9.67
ThredUp (TDUP)
3.0382 of 5 stars
$8.83-1.7%N/A-18.02Moderate Buy$13.00
PURPLE INNOVATION (PRPL)
1.7626 of 5 stars
$0.850.7%N/A-1.08Reduce$1.00
Compare These Stocks  Add These Stocks to My Watchlist